Cerebrolysin Dosage for Intravenous Administration
For intravenous administration of Cerebrolysin, the recommended dosage ranges from 10-30 mL daily, administered as a slow infusion over 60 minutes, with treatment courses typically lasting 10-21 days depending on the clinical indication.
Standard Dosing Protocols
Acute Ischemic Stroke
- Administer 20-30 mL intravenously once daily as a slow infusion over 60 minutes 1, 2, 3
- Treatment duration: 21 consecutive days for acute stroke management 1
- Alternative protocol: Two treatment cycles of daily infusions for vascular dementia, with assessment at 24 weeks 2
Cognitive Impairment and Vascular Dementia
- 20 mL daily via intravenous infusion administered over 60 minutes 2
- Delivered in two treatment cycles as add-on therapy to baseline management 2
- For moderate cognitive impairment: 10 mL diluted in 200 mL physiological solution, given as 20 consecutive daily intravenous injections 4
Traumatic Brain Injury (Mild)
- 30 mL once daily via intravenous infusion over 60 minutes for 5 consecutive days 3
- This higher dose showed significant improvement in cognitive function, particularly long-term memory and drawing function at 3 months post-injury 3
Extrapyramidal Disorders
- 5-10 mL administered intravenously by slow drip every other day for 28 days 5
- This lower-dose, alternate-day regimen demonstrated efficacy in tardive dyskinesia and drug-induced parkinsonism 5
Administration Guidelines
Route and Technique
- Always dilute in physiological saline solution (typically 200 mL) and administer as a slow intravenous infusion 1, 2, 4
- Infusion time should be 60 minutes to ensure proper absorption and minimize adverse effects 2, 3
- Do not administer as rapid IV push 1, 2
Treatment Duration Considerations
- Acute conditions (stroke, TBI): 5-21 days of consecutive daily dosing 1, 3
- Chronic conditions (vascular dementia, cognitive impairment): Treatment cycles with reassessment at 12-24 weeks 2, 4
- Therapeutic effects may have delayed onset, with maximal benefit observed 3 months after treatment completion 4
Clinical Pitfalls and Safety Considerations
Dosing Errors to Avoid
- Do not exceed 30 mL per day - higher doses have not been studied and may increase adverse event risk 3
- Do not administer undiluted - always use appropriate saline dilution 4
- Avoid rapid infusion rates, which may compromise tolerability 2
Monitoring Parameters
- Assess cognitive function using validated scales (MMSE, CASI, ADAS-cog+) at baseline, week 4, and week 12 2, 3
- Monitor for clinical improvement using global assessment tools (CIBIC+) 2
- The drug has demonstrated a favorable safety profile across multiple studies with minimal adverse events 2, 3